Publications

Authors:

Merz, V; Zecchetto, C; Melisi, D

Title:

Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma

Year:

2020

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

FUTURE ONCOLOGY

ISSN of journal:

1479-6694

N° Volume:

17

Number or Folder:

4

Page numbers:

389-402

Keyword:

biliary tract cancer; cholangiocarcinoma; FGFR; FGFR inhibitor; FIGHT-202; pemigatinib

Short description of contents:

The prognosis of patients affected by cholangiocarcinoma is classically poor. Until recently, chemotherapeutic drugs were the only systemic treatment option available, leading to an overall survival lower than 1 year. In recent decades, different genetic alterations have been identified as playing a key role in the oncogenic signaling. A subgroup of intrahepatic cholangiocarcinoma is characterized byFGFRfamily mutations, more frequently represented by gene fusions ofFGFR2. Based on the results of FIGHT-202 trial, in April 2020 the US FDA approved the FGFR inhibitor pemigatinib in advanced previously treated cholangiocarcinoma patients withFGFR2rearrangements, opening the way to targeted therapy in this disease. This review summarizes the body of evidence about the efficacy of pemigatinib in cholangiocarcinoma.Lay abstract Cholangiocarcinoma is cancer that forms in the slender tubes bile ducts that carry the digestive fluid bile. This condition, also known as bile duct cancer, is a type of tumor that is very difficult to treat with common chemotherapy. Intrahepatic cholangiocarcinoma, those tumors occurring in the parts of the bile ducts within the liver, are frequently caused by alterations of a gene calledFGFR2. Pemigatinib is a novel potent drug that selectively inhibits the function of altered FGFR2 and recently demonstrated to be a valid treatment for patients affected by intrahepatic cholangiocarcinoma. Here, we present results about the efficacy of pemigatinib in this disease.

Product ID:

119513

Handle IRIS:

11562/1037037

Last Modified:

November 15, 2022

Bibliographic citation:

Merz, V; Zecchetto, C; Melisi, D, Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma «FUTURE ONCOLOGY» , vol. 17 , n. 4 , 2020 , pp. 389-402

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo